^
Association details:
| Biomarker: | STRN-ALK fusion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Alecensa (alectinib) (ALK inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Primary resistance to alectinib in a patient with STRN-ALK-positive non-small cell lung cancer: A case report
Published date:
05/07/2021
Excerpt:
Here, we report a rare case of striatin (STRN)-ALK-positive NSCLC showing primary resistance to first-line therapy alectinib and limited clinical activity of crizotinib in the alectinib-resistant setting.
DOI:
10.1111/1759-7714.13983
